ACTIVEIMMUNITY

is an organization dedicated to the production of active immunological avian proteins and research activities in the field of modern human immunology. We are engaged in the sustainable innovation competition starting from the ingredients we use, to the products we develop and the technology which we continually improve. We are always open to leading-edge technologies, knowledge and state-of-the-art expertise to expand our research and production portfolio.

ACTIVEIMMUNITY

is based on a number of patented products and techniques belonging to Dr. Ionel Victor PATRASCU, MVD PhD., a leading expert in immunology research.

Dr. Ionel Victor PATRASCU M.V.D., Ph.D.

23 Patents

  • Faculty: Veterinary Medicine, Bucharest, Romania (1963)
  • Doctor of veterinary science (1972), Faculty of Veterinary Medicine
  • Senior Scientist (1991) Institute of Virusology Stefan S. Nicolau, Bucharest, Romania
  • Houghton Poultry Research Station, Hantington, England: 1967, 1969, 1971, 1972. SPF chicken and oncogenic viruses studies.
  • Departament of Poultry Diseases, Cornell University, Ithaca, New York, USA. (1970 – 1971) Oncogenic viruses and tissue cultures.
  • Poultry Laboratories, Davis, California, USA (1971). Marek Disease’s vaccine and tissue culture.
  • Faculty of Veterinary Medicine, Athens, Georgia (1980, 1984) SPF chikens and tissue cultures.
  • Faculty of Veterinary Medicine, Insitute of Veterinary Medicine, Rotterdam, Olanda (1976). Bovine Leukemia Virus, high antigen purification confirmatory assay (1976).
  • Depertament of Veterinary Medicine, Cornell University. Ithaca New York, USA. (1972, 1982, 1983, 1984). Human and chicken oncogenic viruses, cell cultures.
  • Pasteur Institute, Paris, France (1990). Human Immunodeficiency Virus (HIV), virus isolation and characterisation.
  • Department of Veterinary Medicine, Cornell University, Ithaca New York, USA (1993). Human Immunodeficiency Virus (HIV) pathogenicity in human animal cells.
  • Oncological Institute, SanFrancisco, California, USA (1991, 1992). Characterisation of Human Immunodeficiency Virus (HIV) isolates.
  • Center of Disease Control (CDC) Atlanta, Georgia, USA (1992). Outbreake of Romanian Pediatric AIDS.

ABOUT ACTIVEIMMUNITY

Benefits from scientific support of the most important personalities of the medical world in Romania and members of the Romanian Academy of Science.

WHY NOW? WHY US?

Modern medicine must be reconsidered

ACCORDING TO:

  • Environment
  • Genetic susceptibility
  • Immune status
  • Relationship mucous/skin
  • Interrelationship nervous/immune systems
  • Relationship between the cells and the body
  • Relationship between energy transfer and information

IN RELATION WITH:

  • Society
  • Medical international relationship
  • International tourism
  • Regional activity
  • Global interdisciplinary activities

NEW PATENT- 2017

COMPOSITION, PREPARATION METHOD AND EVALUATION OF A COMPLEX IMMUNOGEN NAMED I-SPGA FOR PRODUCTION OF IMMUNOLOGICAL ACTIVE PROTEINS (IAP)
  • New concept in prevention and treatment of infectious diseases and immune deficiency
  • New antigen structures
  • New immunogens: multi and poly
  • Standard active immunologic proteins
  • Personalized active immunologic proteins
  • Immunograma

APPLICATION OF IMMUNOLOGICALLY ACTIVE PROTEINS

  • IgY is an immunoglobulin that was first described in 1893 by Kemplerer. He was the first to describe the mechanism of passive immunity by transferring immunoglobulins against tetanus toxin from chickens to chickens.
  • The name IgY was assigned to avian yolk immunoglobulin after the 1970s by Leslie and Clem, in order to distinguish functionally analogous, but structurally different immunoglobulin identified in mammals (IgG).
  • IgY separation technology with advanced methods is a relatively new field within biochemistry engineering disciplines, which has begun to draw the attention of specialists more than seventy decades ago. Pioneering efforts come largely from Japan, the US and Canada.
  • Since the discovery of egg yolk antibodies, immunoglobulin Y (IgY), in the late 1800s, this process has been harnessed to produce antigen-specific yolk antibodies for numerous applications in the medical and research fields, including in areas such as diagnostics and proteomics.
  • In Romania, the immunologically active proteins group (IAPs) were isolated and studied for the first time by PHD.MVD. I.V. Patrascu.
  • Thanks to recent proprietary technologies we have obtained four times more biological material from that specific quantity and are able to separate some other new valuable proteins with various applications, depending on their native or acquired structure and functions (biological vector, personalized biological vector, specific biological vector).
  • Controlled-size peptides of these proteins have enabled the production of nanogels and biological nanoproducts for internal and external use and largely open the gate of access to parenteral applications.
  • IgY products and IAPs delivered in the form of granules, tablets, solutions, or added as ingredient in functional food have the practical impact for use in several fields: health care, agriculture, cosmetics, food industry.
  • Antibiotic resistance, immunosenescence, autoimmune diseases are just some of the areas of applicability of isolated immunologically active proteins.

IgY AND IAPs (IMMUNOLOGICALLY ACTIVE PROTEINS) – SOLUTIONS IN THE POST-ANTIBIOTIC ERA

  • Post-antibiotics era – in which common infections or minor injuries can kill – it’s far from being just an apocalyptic fantasy, it’s a fact of 21st century (WHO).
  • Antimicrobial resistance (AMR) is an increasingly serious threat to public health worldwide. Governments around the world are making substantial efforts to find solutions to a serious problem that threatens the achievements of modern medicine (WHO).
  • In this context, nosocomial infections are considered to be another enemy.
  • Immunoglobulins Y and immunoproteins IAPs represent a viable solution in the fight against antibiotic resistant microorganisms.

IMMUNOGERONTOLOGY AND IMMUNOSENESCENCE – NEW FIELDS OF APPLICABILITY OF IgY AND IAPs (IMMUNOLOGICALLY ACTIVE PROTEINS)

  • It is well documented that the decline in immunocompetence occurs with age or, rather, is related to the age of humans.
  • In this case, the immune system begins to lose some of its functions and cannot respond quickly or efficiently to stimuli.
  • Alteration of the immune system in the elderly is generally regarded as a deterioration of immunity called immunosenescence.
  • The use of IgY and IAPs by the elderly brings real benefits to maintaining health (as a support for the extension of the thymus functioning period after 65 years, but also for the immunological support of the body in its absence).

A NEW CONCEPT

  • ANTIBIOTIC RESISTANCE

  • URINARY INFECTIONS

  • EPIDERMOLYSIS BULLOSA

  • NOSOCOMIAL INFECTIONS

  • PSORIASIS VULGARIS

  • DIABETES

    akdnsalndajksndkasndkanknxandakjdjkas

OPPORTUNITIES FOR OUR TECHNOLOGY

NEW PATENT- 2017

COMPOSITION AND METHOD OF PREPARING AND EVALUATION OF A COMPLEX IMMUNOGEN I-SPGA FOR IMMUNOLOGICAL ACTIVE PROTEINS PRODUCTION (IAPs)
  • The invention relates to a composition of a new type of immunogenic preparation called I-spga which immunizes the chickens for obtaining immunologically active proteins – IVP (Ionel Victor Patrascu).
  • Immunologically active proteins – IVP can be used to develop a range of biological products indicated in the treatment of:
    • Sensitive or antibiotic resistant urinary tract infections in children and adults;
    • Digestive tract infections;
    • Other mucous membranes, tissues or organs infections;
    • Nosocomial infections;
    • Immune deficiencies;
    • Psoriasis;
    • Epidermolysis bullosa;
    • Other dermatitis;